NCT06470334

Brief Summary

Does adding Dexamethasone to the Periarticular Nerve Group Block in Patients undergoing Total Hip Arthroplasty reduce the dose of ropivacaine?

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Nov 2024

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 17, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 24, 2024

Completed
5 months until next milestone

Study Start

First participant enrolled

November 7, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2025

Completed
Last Updated

July 11, 2025

Status Verified

December 1, 2024

Enrollment Period

5 months

First QC Date

June 17, 2024

Last Update Submit

July 8, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time to first rescue opioid analgesia

    Time after surgery when the patient needs opiate for the first time

    48 hours after surgery

Secondary Outcomes (22)

  • Total Opioid Consumption

    48 hours after surgery

  • Numerical Rating Scale [range 0:10]

    4 hours after surgery

  • Numerical Rating Scale [range 0:10]

    8 hours after surgery

  • Numerical Rating Scale [range 0:10]

    12 hours after surgery

  • Numerical Rating Scale [range 0:10]

    24 hours after surgery

  • +17 more secondary outcomes

Study Arms (2)

Ropivacaine

ACTIVE COMPARATOR

Ultrasound-guided PENG block - 20ml 0,2% ropivacaine

Drug: Ropivacaine

Ropivacaine + Dexamethasone

ACTIVE COMPARATOR

Ultrasound-guided PENG block - 10ml 0,2% ropivacaine + 4mg Dexamethasone

Drug: Ropivacaine+Dexamethasone

Interventions

Ultrasound-guided PENG block - 20ml 0,2% ropivacaine

Also known as: Pericapsular Nerve Group Block
Ropivacaine

Ultrasound-guided PENG block - 10ml 0,2% ropivacaine + 4mg Dexamethasone

Also known as: Pericapsular Nerve Group Block
Ropivacaine + Dexamethasone

Eligibility Criteria

Age65 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • patients scheduled for total hip arthroplasty
  • patients aged \>65 and \<100 years
  • patients able to provide informed consent
  • patients able to reliably report symptoms to the research team

You may not qualify if:

  • inability to provide first-party consent due to cognitive impairment or a language barrier

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Poznan University of Medical Sciences

Poznan, Poznań, 61-701, Poland

Location

MeSH Terms

Conditions

Osteoarthritis, Hip

Interventions

Ropivacaine

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Malgorzata Reysner, M.D. Ph.D.

    Poznań University of Medical Sciences

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 17, 2024

First Posted

June 24, 2024

Study Start

November 7, 2024

Primary Completion

March 31, 2025

Study Completion

April 30, 2025

Last Updated

July 11, 2025

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will share

Individual participant data will be available following study completion

Shared Documents
STUDY PROTOCOL
Time Frame
Following study completion
Access Criteria
Eligible researchers

Locations